Cristina Whitt
Family · Pulaski, VANPI 1194385070
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 767 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 51 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 767 payments — averaging $15.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$1K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Pfizer$559
- Amgen$510
- plus $5K from 45 others
What the payments were for
- Food & beverage$11,688100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,688 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 79 | $101,005 |
| EliquisApixaban | 114 | $95,890 |
| RybelsusSemaglutide | 46 | $62,874 |
| Austedo XrDeutetrabenazine | 12 | $57,632 |
| MounjaroTirzepatide | 48 | $49,935 |
| JardianceEmpagliflozin | 40 | $40,596 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $31,545 |
| Repatha SureclickEvolocumab | 20 | $30,084 |
| TrulicityDulaglutide | 14 | $22,951 |
| VraylarCariprazine Hcl | 16 | $22,700 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $22,353 |
| TradjentaLinagliptin | 13 | $19,980 |
| LinzessLinaclotide | 29 | $17,521 |
| XareltoRivaroxaban | 25 | $16,778 |
| NexlizetBempedoic Acid/Ezetimibe | 21 | $14,721 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,256 | $163,879125 claims |
| PfizerEliquis | $559 | $95,890114 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,038 | $72,88762 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $117 | $66,91165 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $166 | $57,63212 claims |
| AbbVieVraylar, Linzess, Ubrelvy, Synthroid | $1,572 | $53,38291 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $1,331 | $45,64978 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $278 | $40,35841 claims |
| Johnson & JohnsonXarelto | $204 | $16,77825 claims |
| Esperion Therapeutics, Inc.Nexlizet | $128 | $14,72121 claims |
| Astellas Pharma US IncMyrbetriq | $181 | $13,30127 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $424 | $13,06413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.
Other family in Pulaski
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
- Casey SharpDanville$63K
- Norman JacobowitzManassas$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.